NY-ADACORE
13.6.2024 11:23:28 CEST | Business Wire | Press release
AdaCore https://www.adacore.com/ is thrilled to be part of the Safety-Critical Rust Consortium alongside The Rust Foundation, Arm, Ferrous Systems, OxidOS, Synopsys, HighTec EDV-Systeme GmbH, TrustInSoft, Veecle, and Woven by Toyota. The primary objective of this group will be to support the responsible use of the Rust programming language in safety-critical software — systems whose failure can impact human life or cause severe environmental or property harm.
Safety-Critical Rust Consortium Membership is open to Rust Foundation member organizations and other invitees, such as industry, academic, and legal experts.
Work under the consortium will begin with the creation of a public charter and goals, and meeting minutes will be published on an ongoing basis. The Safety-Critical Rust Consortium will liaise with the Rust Project through Rust Foundation Project Directors and members of Rust Project teams. The Consortium’s scope, which will be fully delineated in the charter, may include the development of guidelines, linters, libraries, static analysis tools, formal methods, and language subsets to meet industrial and legal requirements. The Consortium’s deliverables will be developed and licensed in a manner compatible with other Rust Project endeavors.
The group may further shepherd Rust Foundation-funded implementation work, including grants to existing academic teams or FOSS projects. Any Rust Foundation-funded work will be submitted upstream, licensed as FOSS, and any specifications will be freely available. The group will further attempt to coordinate with and expand on existing safety-critical projects and standards including SAE JA1020.
Programming-language safety refers to a language’s ability to prevent errors or undefined behaviors at compile time or runtime. On the other hand, "safety-critical" refers to a system’s ability to operate without causing accidents or catastrophic failures that will result in harm to people, property or the environment. So, while safety-critical systems rely on languages that emphasize safety and security, such as Rust, programming tools are only one component of the overall strategy.
Tony Aiello is the Product Manager at AdaCore,
“At AdaCore, we focus on industries where safety, security, and reliability are paramount including automotive, aviation, and space. AdaCore has decades of experience serving these industries with Ada, SPARK, and C++. Participating in the Safety-Critical Rust Consortium enables us to leverage our expertise to help the Rust community best position itself to serve the safety-critical community’s needs.”
About AdaCore
Everything we do at AdaCore is centered around helping developers build safe, secure and reliable software. With over 30 years of experience working with the most respected companies in industries such as aerospace, defense and railways, we build tools and provide services that ease the complex and often difficult process of developing high-integrity software. As the need for truly secure and reliable applications expands into industries such as automotive, medical, energy, and IoT, we’re excited to bring our time-tested technologies, expertise and services to help a whole new generation of developers.
About The Rust Foundation
The Rust Foundation is an independent nonprofit dedicated to the safety, security, sustainability, and health of the Rust Programming language and the people who use it. Through close partnerships with organizations passionate about Rust and the growing Rust Project and community, the Rust Foundation is helping forge a better open-source future with Rust.
Visit the Rust Foundation website to learn more. Follow the Rust Foundation on X (formerly known as Twitter) and on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613424332/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
